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We screened 14,008 adult nonsurgical patients for Staphylococcus aureus nasal carriage at hospital admission
and assessed them for invasive S. aureus disease and in-hospital mortality. Multilocus sequence typing was
performed on endogenous invasive strains and nasal strains of matched asymptomatic carriers to investigate
whether virulent clones could be identified in nasal carriers. Clonal complex (CC) 45 was significantly un-
derrepresented (odds ratio [OR], 0.16 [95% confidence interval {CI}, 0.04–0.59]) and CC30 was overrepresented
(not statistically significant) among invasive strains (OR, 1.91 [95% CI, 0.91–4.0]). The distribution of CCs
of invasive S. aureus strains in noncarriers did not differ from that in carriers. Those infected with S. aureus
strains belonging to a CC had higher mortality than those infected with strains not belonging to a CC (P !
), which indicates the coevolution of S. aureus virulence and spread in humans..05
Staphylococcus aureus is a leading cause of nosocomial
infections, varying from superficial wound infections
to invasive disease, such as deep abscesses, osteomye-
litis, and bacteremia [1]. These infections lead to pro-
longed hospital stays, increased antibiotic use, and in-
creased medical costs [2]. S. aureus nasal carriers have
a 3-fold increased risk of acquiring nosocomial S. au-
reus bacteremia, compared with noncarriers, but they
have lower mortality when infection occurs [3]. This
higher survival of carriers may be due to partial im-
munity. Alternatively, S. aureus strains from asymptom-
atic nasal carriers of S. aureus may belong to a less
virulent genotype, compared with strains from nasal
carriers with proven invasive disease.
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We, therefore, wanted to investigate whether certain
S. aureus clones found in S. aureus nasal carriers are
more likely than others to cause invasive disease. We
also investigated whether invasive S. aureus disease in
noncarriers may be caused by a specific clone acquired
during hospitalization. We used a microarray-based
method for multilocus sequence typing (MLST) to an-
alyze a collection of S. aureus strains described else-
where that were isolated from a cohort of patients ad-
mitted to the hospital [3–5].
PATIENTS, MATERIALS, AND METHODS
Study design
We performed a nested case-control study in a cohort
of 14,008 adult nonsurgical patients who were screened
for S. aureus nasal carriage at hospital admission [3,
5]. The study was performed in 4 teaching hospitals in
separate regions of The Netherlands from 1 February
1999 to 1 February 2001. All patients were monitored
for the development of invasive S. aureus disease by
checking microbiological data on a weekly basis, as de-
scribed elsewhere [3, 5]. Invasive disease was defined
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Table 1. Characteristics of the study population.
Characteristic
Case patients
(n p 60)
Control subjects
(n p 118)a
Noncarriers
(n p 34)
Male sex, no. (%) 33 (55.0) 65 (55.1) 24 (70.6)
Mean age (SD), years 53 (17) 53 (17) 64 (17)b
Site of hospital admission, no. (%)
Nijmegen 17 (28.3) 33 (28.0) 12 (35.3)
Amsterdam 8 (13.3) 16 (13.6) 5 (14.7)
Breda 5 (8.3) 10 (8.5) NDc
Rotterdam 30 (50.0) 59 (50.0) 17 (50.0)
Origin of strain, no. (%)
Blood 55 (91.7) 0 (0.0) 34 (100.0)
Other sterile site 5 (8.3) 0 (0.0) 0 (0.0)
NOTE. Case patients are carriers who acquired invasive Staphylococcus aureus disease caused by
their own nasal strain during hospitalization, control subjects are carriers who did not acquire S. aureus
invasive disease, and noncarriers are those who were not colonized by S. aureus in the nose at admission
but did develop invasive S. aureus disease during hospitalization. ND, not done.
a Two control subjects were found to have S. aureus infection at a later date and were excluded from
further analysis.
b Noncarriers were significantly older than case patients ( ).Pp .005
c The hospital in Breda did not store invasive S. aureus strains from noncarriers.
as being present when S. aureus was cultured from blood or
from pus present in a normally sterile site. Medical ethical
approval was obtained from all participating centers.
For each case patient with invasive disease, 2 control subjects
were included who were matched by the presence of S. aureus
nasal carriage, the hospital of admission, the date of admission
(1 month), sex, age group (5 years), and the absence of
S. aureus infection during follow-up (until 6 weeks after dis-
charge). If 12 matched control subjects were found, those clos-
est in age to the case patient were selected. Nasal strains from
carriers and invasive strains from noncarriers were genotyped
by pulsed-field gel electrophoresis (PFGE), and the resulting
data were interpreted in accordance with standard criteria [6].
MLST was performed on genetically similar, as determined by
PFGE, invasive strains from carriers and on nasal strains from
carriers who did not develop invasive disease (asymptomatic
carriers). In addition, invasive strains cultured from blood or
deep foci of infection from noncarriers were analyzed by MLST.
MLST. We used an oligonucleotide array for MLST of S.
aureus, as described elsewhere [4]. Briefly, DNA was extracted
using lysostaphine and the QIAamp DNA Minikit (Qiagen).
DNA was used in a multiplex polymerase chain reaction (PCR)
with specific primers targeting the 7 housekeeping genes, as
defined by Enright et al. [7]. PCR products were fragment-
ed and labeled with a new DNA amplicon labeling technique
(bioMe´rieux), were purified with the QIAquick Nucleotide Re-
moval Kit (Qiagen), and were hybridized with the oligoprobe
arrays in the GeneChip Fluidics Station (Affymetrix) [4]. Each
probe array was stained with R-phycoerythrin–labeled strep-
tavidin (Dako), and the signal was measured with a GeneAr-
ray scanner (Agilent). Probe array cell intensities, base call,
sequence determination, and reports were generated by func-
tions available in GeneChip (Affymetrix). A candidate allele
selection index was determined by the percentage of identity
between the experimentally derived sequence and the distinct
reference sequence tiled on the array.
For some housekeeping genes, the oligomediated MLST pro-
cedure can generate ambiguous results, because polymorphisms
can be present in the 10 nucleotides proximal to the 5′ and 3′
ends of the amplicons [7]. Genes with these polymorphisms
are not recognized by the oligoprobes. In such cases, the entire
housekeeping gene was reamplified, and both strands of the am-
plicons were sequenced to identify possible polymorphisms [4].
Statistical analysis
Comparison of MLST results was performed with BURST soft-
ware, as described elsewhere [8]. Data were analyzed with SPSS
(version 10.0; SPSS). Frequencies were compared with the x2
test, and continuous variables were compared with Student’s t
test. was considered to be statistically significant. OddsP ! .05
ratios with 95% confidence intervals (CIs) were calculated for
the case-control study.
RESULTS
General
The demographic data of the 60 case patients and 118 control
subjects are summarized in table 1. Two control subjects were
excluded, because they were later found to have S. aureus in-
fection, and they were not replaced by new control subjects.
Most invasive strains (91.7%) were cultured from blood. Ad-
ditionally, 34 invasive strains that were cultured from blood
1198 • JID 2005:192 (1 October) • Wertheim et al.
Figure 1. Dendrogram showing the relatedness of Staphylococcus aureus sequence types
from hospitalized nonnasal carriers of S. aureus and were de-
scribed elsewhere [3] were selected for MLST. Five strains from
the original cohort were lost and therefore were not analyzed.
None of the cultured S. aureus strains was methicillin resistant.
Sequence types, invasive disease, and mortality
Overall, 32 different sequence types (STs) were identified (figure
1). Nine STs accounted for 80% of all tested strains, and 3 STs
(30, 15, and 45) were the most prevalent (20%, 15%, and 12%,
respectively). There were no significant differences in the dis-
tribution of STs per hospital (data not shown). STs were grouped
by BURST analysis into clonal complexes (CCs), as is shown
in table 2. Although the results of the BURST analysis regard-
ed STs 5, 9, 12, 15, and 22 as singletons, we classified them
as CCs, as was done in a previous study [8]. Only CC45 was
significantly more prevalent in noninvasive strains (odds ratio
[OR], 0.2 [95% CI, 0.04–0.6]). Most invasive strains belonged
to CC30, and many were singletons. Invasive strains from non-
carriers did not differ markedly from invasive strains from
carriers in the distribution of CCs (table 2).
The overall mortality in noncarriers was higher than that in
carriers (table 3) ( ), as described elsewhere [3]. By useP ! .001
of MLST analysis, we could not identify a specific clone in
noncarriers that could explain the higher in-hospital mortality
in this group. However, there was significantly higher mortality
in carriers and noncarriers infected with S. aureus strains be-
longing to a CC (20/69 [29.0%]), compared with that in those
infected with strains classified as singletons or new STs (1/25
[4.0%]; ).P ! .05
DISCUSSION
In a previous study, patients were screened for S. aureus nasal
carriage at admission in 4 teaching hospitals and were followed
for the development of nosocomial invasive S. aureus disease.
In the present study, invasive S. aureus strains from carriers were
compared, by MLST, with nasal strains isolated from matched
control subjects who did not develop invasive S. aureus disease.
The STs of invasive S. aureus strains from noncarriers were de-
fined as well. The distribution of the CCs was comparable with
that found in other studies [8, 9].
Overall, no major CC could be identified that was responsi-
ble for invasive S. aureus disease. However, 35.0% of invasive
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Table 2. Distribution of identified clonal complexes (CCs).
CC
Case
patients
Control
subjects OR (95% CI) Noncarriers
1 1 (1.7) 4 (3.4) 0.5 (0.02–4.8) 4 (11.7)
5 6 (10.0) 5 (4.2) 2.5 (0.6–10.0) 1 (2.9)
9 1 (1.7) 1 (0.8) 2.0 (0.01–74.0) 1 (2.9)
12 1 (1.7) 0 (0.0) … 0 (0.0)
15 8 (13.3) 17 (14.4) 0.9 (0.3–2.4) 7 (20.6)
22 0 2 (1.7) 0.0 (0.0–8.1) 0 (0.0)
25 1 (1.7) 6 (5.1) 0.3 (0.01–2.8) 3 (8.8)
30 21 (35.0) 26 (22.0) 1.9 (0.9–4.0) 6 (17.6)
45 3 (5.0) 29 (24.6) 0.2 (0.04–0.6)a 5 (14.7)
Singletons 17 (28.3) 28 (23.7) 1.3 (0.6–2.7) 6 (17.6)
New ST 1 (1.7) 0 (0.0) … 1 (2.9)
Total 60 118 … 34
NOTE. Data are no. (%) of strains, unless otherwise indicated. CC1 in-
cludes sequence types (STs) 1, 3, 81, 188, and 573; CC25 includes STs 25
and 26; CC30 includes STs 30, 34, and 39; CC45 includes STs 45, 46, 47, and
53; singletons include STs 7, 8, 50, 97, 120, 182, 500, 501, and 502; and new
STs include the following allelic profiles: 18-33-6-2-7-13-2 and 3-14-6-2-14-13-
x. CI, confidence interval; OR, odds ratio.
a .Pp .001
Table 3. Mortality data of carriers and noncarriers with in-
vasive Staphylococcus aureus disease, by clonal complex (CC).
CC
In-hospital mortality
Carriers Noncarriers Total
1 1/1 (100.0) 2/4 (50.0) 3/5 (60.0)
5 1/6 (16.7) 0/1 (0.0) 1/7 (14.3)
9 0/1 (0.0) 1/1 (100.0) 1/2 (50.0)
12 0/1 (0.0) 0/0 (0.0) 0/1 (0.0)
15 1/8 (12.5) 3/7 (42.9) 4/15 (26.7)
25 1/1 (100.0) 1/3 (33.3) 2/4 (50.0)
30 2/21 (9.5) 4/6 (66.7) 6/27 (22.2)
45 0/3 (0.0) 3/5 (60.0) 3/8 (37.5)
Singletons 0/17 (0.0) 1/6 (16.7) 1/23 (4.3)
New ST 0/1 (0.0) 0/1 (0.0) 0/2 (0.0)
Total 6/60 (10.0) 15/34 (44.1) 21/94 (22.3)
NOTE. Data are no./total (%) of strains. There was significantly higher
mortality in noncarriers, compared with that in carriers ( , x2 test). NoP ! .001
specific CC could be identified that was associated with higher mortality in
noncarriers. CC1 includes sequence types (STs) 1, 3, 81, 188, and 573; CC25
includes STs 25 and 26; CC30 includes STs 30, 34, and 39; CC45 includes
STs 45, 46, 47, and 53; singletons include STs 7, 8, 50, 97, 120, 182, 500,
501, and 502; and new STs include the following allelic profiles: 18-33-6-2-7-
13-2 and 3-14-6-2-14-13-x.
strains belonged to ST30 (not statistically significant). Inter-
estingly, we did identify a CC (45) that was significantly more
prevalent among nasal strains. This finding is supported by
data in a study by Melles et al. [9]. They found that CC45 was
present in 21% of asymptomatic carriers and in only 13% of
invasive strains (not statistically significant) [9]. We could not
identify a CC that was significantly more prevalent in invasive
strains from noncarriers than in other strains.
We reported elsewhere that there was considerably higher
mortality in noncarriers with invasive S. aureus strains, com-
pared with that in carriers with invasive disease in the same
cohort [3]. No single CC could be identified that could explain
the higher mortality in this patient category. But this analysis
is not definite, because some CCs had small numbers. How-
ever, in the present study, mortality was significantly higher in
carriers and noncarriers infected with S. aureus strains belong-
ing to a CC, compared with mortality in those infected with
strains not belonging to a CC (29.0% vs. 4.0%). A multivariate
analysis did not alter this finding (data not shown).
There is some controversy regarding whether ST8 belongs
to a CC (CC8). A recent overview of the clonality of S. aureus
classifies this ST as a singleton, like we did [8]. Other studies
classify ST8 as a CC [10]. In the present study, when we re-
garded ST8 as a CC, we still found much higher mortality in
carriers and noncarriers infected with S. aureus strains belong-
ing to a CC (20/77 [26.0%]), compared with mortality in those
infected with strains classified as singletons or new STs (1/17
[5.9%]; ).Pp .07
This finding indicates that staphylococcal clones that have
successfully spread in humans—that is, have evolved into prev-
alent CCs or lineages—are those that may have more virulence
factors associated with lethality of S. aureus disease. Addition-
al screening of the staphylococcal genome for virulence factors
could aid in identifying the putative factor(s) responsible for the
higher mortality caused by strains belonging to CCs. Although
we did not correct for underlying disease in the present study
(data not available), recent data indicate that underlying disease
is not as important in predicting mortality as was previously
thought [3]. Control subjects who fit the criteria for the present
study were picked at random, to exclude a biased selection.
Feil et al. also identified CC30 as a major CC in invasive
nosocomial disease [8]. They attributed this observation to the
widespread presence of EMRSA-16 within this CC [7, 8]. How-
ever, in the present study, no methicillin-resistant S. aureus
(MRSA) strains were identified—and the prevalence of MRSA
strains is very low in The Netherlands [11]—so methicillin
resistance does not explain this finding. Clearly, CC30 is a
successful S. aureus lineage, irrespective of its methicillin re-
sistance. Due to the abundance of strains belonging to CC30,
as was found in our study and by Melles et al. [9], the chances
that this lineage will acquire a Staphylococcus cassette chro-
mosome mec (SCCmec) are likely high. Once a SCCmec is ac-
quired, these CC30 MRSA strains can replace CC30 methicillin-
susceptible strains easily in settings with high antibiotic use,
including hospitals.
Peacock et al. [12] compared 155 S. aureus isolates from
patients with invasive disease with carriage isolates from healthy
individuals in the same cohort that Feil et al. studied [8]. Pea-
cock et al. proposed that allelic variants of a polymorphic lo-
cus can make different contributions to the disease process,
although it remains unclear how this is done. They also found
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evidence for considerable horizontal transfer of genes against
a clonal background. It is now well established that, within and
between S. aureus clones, there is a significant level of exchange
of mobile DNA that codes for virulence and resistance [13–
15]. Melles et al. showed that all clones can cause life-threat-
ening infections, but certain clones are more virulent than oth-
ers [9]. It would be interesting to investigate whether there is
a difference in competence for the uptake of (mobile) DNA
between clones.
By MLST, we could not identify any S. aureus CC that was
more likely than other CCs to cause invasive disease. We did
find that CC45 was more prevalent in asymptomatic carriers.
CC30 was also prevalent, and this prevalence was independent
of methicillin resistance. There were no prevalent clones of
invasive S. aureus strains in noncarriers and no specific clone
that could explain the higher in-hospital mortality. However,
overall mortality, irrespective of carriage status, was significant-
ly higher for carriers and noncarriers infected with strains be-
longing to a CC, which indicates the coevolution of S. aureus
virulence and spread in humans.
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